Source comparison
CJC-1295 vs Other GH-Releasing Peptides
Several peptides stimulate growth hormone release through different mechanisms. Choosing the right one depends on your goal, budget, and tolerance for injection frequency. CJC-1295 with DAC GHRH + albumin binding 1-2 mg 1-2x/week Phase 1/2 trial $80-150 CJC-12
This comparison does not assign a generated winner or score.
- Several peptides stimulate growth hormone release through different mechanisms. Choosing the right one depends on your goal, budget, and tolerance for injection frequency.
- CJC-1295 with DAC
- GHRH + albumin binding
- 1-2 mg
- 1-2x/week
- Phase 1/2 trial
- $80-150
- CJC-1295 no DAC
- Modified GHRH
- 25-30 min
- 1-3x/day
- Preclinical + community
- $40-100
- Sermorelin
- GHRH (1-29)
- ~11 min
- 200-500 mcg
- 1x/day
- FDA-approved (discontinued)
- $60-120
- Tesamorelin
- Modified GHRH (1-44)
- ~26 min
- 2 mg
- Phase 3 trials
- $200-500
- Ghrelin receptor
- ~2 hours
- Phase 2 trial
- $40-80
- MK-677
- Oral ghrelin mimetic
- ~24 hours
- 10-25 mg oral
- Phase 2 trials
- $30-60
- CJC-1295 without DAC occupies the sweet spot: longer-acting than sermorelin (which degrades too fast for reliable clinical effect), shorter-acting than DAC (which sacrifices pulsatility), and considerably cheaper than tesamorelin (the only FDA-approved option in this class).
- MK-677 is the convenience option: oral dosing, once daily, no injections. The tradeoff is that it elevates cortisol and appetite more than ipamorelin, and its 24-hour half-life creates continuous rather than pulsatile GH elevation. For users who cannot commit to daily injections, MK-677 is the practical alternative. For those willing to inject, CJC-1295 no DAC plus ipamorelin remains the standard.